 The authors have developed a novel method to deliver therapeutic mRNA using lipid nanoparticles, LNPs, which can be taken up by cells and translated into proteins. They also found that these particles can be extended by cells' own vehicles, known as extracellular vesicles, EVs, allowing them to travel longer distances and reach more cells. Furthermore, they discovered that EVs can be used to deliver therapeutic mRNA to multiple organs, including the liver, without causing any side effects. Finally, they showed that EVs from cardiac progenitor cells were the most effective at delivering therapeutic mRNA to the heart, while minimizing inflammation. This article was authored by Mohamed Nawaz, Sapita Hidarken-Hagval, Binyapa Tangruxa, and others.